One to Watch: Veradermics Raises $150M in Series C Financing; Shares Positive Preliminary Phase 2 Data for Oral Minoxidil in Pattern Hair Loss
Veradermics has completed an oversubscribed $150 million Series C financing. The financing was designed to support the registrational development and planned New Drug Application (NDA) submission for Veradermics’ lead investigational product, VDPHL01.